

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-238) OGALVIBART
 PRONUNCIATION oh gal' vi bart
 THERAPEUTIC CLAIM Treatment of SARS-CoV-2 infection

CHEMICAL NAME

Immunoglobulin G1 [430-leucine,436-serine,de-449-lysine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal C135 γ 1-chain), disulfide with human monoclonal C135 κ -chain, dimer (Source: CAS)

STRUCTURAL FORMULA

Heavy chain X, X''

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYAMHWVRQA	PGKGLEWVAV	50
IPFDGRNKYY	ADSVTGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCASSS	100
GYLFDSDYWG	QGLTLTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHNKPSN	TKVDRVPEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMIISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSREEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVL	HEALHSHYTQ	KLSLSLSPG	448

Light chain X', X''

DIQMTQSPST	LSASVGDRTV	ITCRASQGIS	NWLAWFQQKP	GKAPKLLIYE	50'
ASSLESGVPS	RFGSGSGSTE	FTLTISSLQP	DDFATYYCQQ	YNSYPWTFGQ	100'
GTKVEIKRTV	AAPSVFIAPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22''-96''	23'-88'	23'''-88'''	134'-194'	134'''-194'''	146-202	146''-202''
222-214'	222''-214''	228-228''	231-231''	263-323	263'''-323'''	369-427	369''-427''

Glycosylation sites (N)

299 299''

MOLECULAR FORMULA $C_{6450}H_{9934}N_{1718}O_{2012}S_{42}$

MOLECULAR WEIGHT 145.1 kDa

TRADEMARK None as yet

SPONSOR Bristol Myers Squibb

CODE DESIGNATIONS BMS-986414, IM051, C135-LS

CAS REGISTRY NUMBER 2599039-60-6

UNII SC4RQX96VW

WHO NUMBER 12361

gbk